SG11201907298WA - Methods and compositions for gene transfer across the vasculature - Google Patents
Methods and compositions for gene transfer across the vasculatureInfo
- Publication number
- SG11201907298WA SG11201907298WA SG11201907298WA SG11201907298WA SG11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA SG 11201907298W A SG11201907298W A SG 11201907298WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- north
- pct
- publication
- date
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000005166 vasculature Anatomy 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 4
- 108090000565 Capsid Proteins Proteins 0.000 abstract 2
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 101100064317 Arabidopsis thaliana DTX41 gene Proteins 0.000 abstract 1
- 235000014036 Castanea Nutrition 0.000 abstract 1
- 241001070941 Castanea Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003618 cortical neuron Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459286P | 2017-02-15 | 2017-02-15 | |
| PCT/US2018/018381 WO2018152333A1 (en) | 2017-02-15 | 2018-02-15 | Methods and compositions for gene transfer across the vasculature |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907298WA true SG11201907298WA (en) | 2019-09-27 |
Family
ID=63169716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907298WA SG11201907298WA (en) | 2017-02-15 | 2018-02-15 | Methods and compositions for gene transfer across the vasculature |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11905312B2 (https=) |
| EP (1) | EP3583220A4 (https=) |
| JP (2) | JP7291397B2 (https=) |
| KR (1) | KR20190117571A (https=) |
| CN (2) | CN118978574A (https=) |
| AU (1) | AU2018221738B2 (https=) |
| BR (1) | BR112019016769A2 (https=) |
| CA (1) | CA3052829A1 (https=) |
| EA (1) | EA038695B1 (https=) |
| IL (2) | IL312788A (https=) |
| MX (1) | MX2019009720A (https=) |
| SG (1) | SG11201907298WA (https=) |
| WO (1) | WO2018152333A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| BR112018003665A2 (en) | 2015-09-28 | 2018-09-25 | The University Of North Carolina At Chapel Hill | methods and compositions for antibody evasion viral vectors |
| MX2020002148A (es) * | 2017-08-25 | 2020-07-20 | Ovid Therapeutics Inc | Vectores adenoasociados recombinantes. |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| CN112543766A (zh) | 2018-04-03 | 2021-03-23 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| US20210363191A1 (en) | 2018-04-03 | 2021-11-25 | Stridebio, Inc. | Antibody-evading virus vectors |
| IL278598B2 (en) | 2018-05-11 | 2025-11-01 | Massachusetts Eye & Ear Infirmary | Altering tissue tropism of adeno-associated viruses |
| CN112703198B (zh) | 2018-07-11 | 2025-05-30 | 布里格姆妇女医院 | 用于跨血脑屏障递送试剂的方法和组合物 |
| WO2020068990A1 (en) | 2018-09-26 | 2020-04-02 | California Institute Of Technology | Adeno-associated virus compositions for targeted gene therapy |
| US12281321B2 (en) | 2018-09-28 | 2025-04-22 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| KR20210130158A (ko) * | 2019-01-31 | 2021-10-29 | 오레곤 헬스 앤드 사이언스 유니버시티 | Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법 |
| BR112021015312A2 (pt) | 2019-02-04 | 2021-11-09 | Freeline Therapeutics Ltd | Polinucleotídeos, partícula viral e composição |
| BR112021018776A2 (pt) | 2019-03-21 | 2021-11-30 | Stridebio Inc | Vetores de vírus adenoassociado recombinante |
| TW202102526A (zh) * | 2019-04-04 | 2021-01-16 | 美商銳進科斯生物股份有限公司 | 重組腺相關病毒及其用途 |
| KR20220012231A (ko) * | 2019-04-24 | 2022-02-03 | 리젠엑스바이오 인크. | 완전-인간 번역 후 변형된 항체 치료제 |
| JP7785352B2 (ja) * | 2019-08-14 | 2025-12-15 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 遺伝子治療のためのａａｖカプシドバリアント |
| US12570998B2 (en) | 2019-09-09 | 2026-03-10 | Massachusetts Eye & Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (AAV) and the AAV receptor (AAVR) for altered bio-distribution of AAV |
| KR20220083714A (ko) | 2019-10-17 | 2022-06-20 | 스트라이드바이오 인코포레이티드 | 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터 |
| EP4051324A4 (en) * | 2019-10-28 | 2023-11-29 | University Of Florida Research Foundation, Incorporated | Gene therapy vectors |
| PH12022551247A1 (en) * | 2019-11-22 | 2023-11-13 | Childrens Hospital Philadelphia | Adeno-associated viral vector variants |
| AU2021206256A1 (en) | 2020-01-10 | 2022-07-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| WO2021163357A2 (en) | 2020-02-13 | 2021-08-19 | Tenaya Therapeutics, Inc. | Gene therapy vectors for treating heart disease |
| MY209860A (en) | 2020-02-13 | 2025-08-07 | Tenaya Therapeutics Inc | Gene therapy vectors for treating heart disease |
| TW202142554A (zh) * | 2020-02-25 | 2021-11-16 | 澳洲兒童醫學研究所 | 腺相關病毒蛋白殼多肽及載體 |
| AR122013A1 (es) * | 2020-05-05 | 2022-08-03 | Univ Duke | Composiciones de virus adenoasociados compatibles entre especies y métodos para su uso |
| EP4200408A1 (en) | 2020-08-19 | 2023-06-28 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of rett syndrome |
| JP2023545384A (ja) * | 2020-10-07 | 2023-10-30 | リジェネックスバイオ インコーポレイテッド | 中枢神経系または筋肉送達のための組換えアデノ随伴ウイルス |
| WO2022076750A2 (en) * | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns or muscle delivery |
| US20240060087A1 (en) * | 2021-01-08 | 2024-02-22 | Massachusetts Eye And Ear Infirmary | Methods and compositions for modulating the interaction between adeno-associated virus (aav) and the aav receptor (aavr) for altered bio-distribution of aav |
| WO2022155358A1 (en) * | 2021-01-13 | 2022-07-21 | Duke University | Compositions for and methods of improving fluid flux in the brain |
| AU2022307365A1 (en) | 2021-07-08 | 2024-02-01 | Tenaya Therapeutics, Inc. | Optimized expression cassettes for gene therapy |
| US20250281639A1 (en) * | 2021-07-14 | 2025-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating chronic pain and for retrograde transduction of neurons |
| CN113563430B (zh) * | 2021-07-30 | 2022-05-31 | 上海信致医药科技有限公司 | 用于治疗眼部疾病的基因递送系统及其应用 |
| CN113480615B (zh) * | 2021-07-30 | 2022-05-31 | 上海信致医药科技有限公司 | 高视网膜亲和性的新型腺相关病毒衣壳蛋白及其应用 |
| IL310949A (en) * | 2021-08-20 | 2024-04-01 | Biocad Joint Stock Co | A method for preparing an adapted adeno-associated virus envelope |
| AR126839A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta |
| US20240425549A1 (en) * | 2021-08-25 | 2024-12-26 | Children's Medical Research Institute | Modified aav capsid polypeptides and vectors |
| MX2024002379A (es) * | 2021-08-25 | 2024-04-29 | Childrens Medical Res Institute | Cápsides y vectores de aav modificados. |
| WO2023060272A2 (en) * | 2021-10-07 | 2023-04-13 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| CN114516901B (zh) * | 2022-03-11 | 2023-01-17 | 上海勉亦生物科技有限公司 | 一种神经系统高亲和性的aav载体及其应用 |
| WO2023201277A1 (en) * | 2022-04-14 | 2023-10-19 | Regenxbio Inc. | Recombinant adeno-associated viruses for cns tropic delivery |
| WO2024054864A1 (en) | 2022-09-06 | 2024-03-14 | Tenaya Therapeutics, Inc. | Cardioprotective heart disease therapies |
| KR102855674B1 (ko) * | 2022-10-06 | 2025-09-08 | 주식회사 글루진테라퓨틱스 | 폐 기관지 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터 |
| WO2024215653A1 (en) | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Guide rnas, vectors, and virions for targeting mutations in the pln gene |
| WO2024215655A1 (en) | 2023-04-10 | 2024-10-17 | Tenaya Therapeutics, Inc. | Cardioprotective bag3 therapies |
| AU2024294136A1 (en) * | 2023-07-20 | 2026-02-05 | Children's Medical Research Institute | Modified cardiotropic aav capsid polypeptides and vectors |
| KR102868933B1 (ko) * | 2023-11-08 | 2025-10-14 | 주식회사 글루진테라퓨틱스 | 성상세포 특이적 유전자 전달이 가능한 아데노부속바이러스 벡터 |
| KR102844372B1 (ko) * | 2023-12-06 | 2025-08-11 | 주식회사 글루진테라퓨틱스 | 뇌 성상교세포 특이적 유전자 전달이 가능한 아데노부속바이러스 변이체와 이의 응용 |
| WO2025147741A1 (en) * | 2024-01-11 | 2025-07-17 | Children's Medical Research Institute | Aav capsids and vectors for transduction of cells |
| CN119405806A (zh) * | 2024-10-25 | 2025-02-11 | 南通大学 | 小肌营养蛋白域含2抑制剂在制备促进神经生长药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340230T3 (es) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| WO2004027019A2 (en) * | 2002-05-01 | 2004-04-01 | University Of Florida Research Foundation, Inc. | Improved raav expression systems for genetic modification of specific capsid proteins |
| EP2396343B1 (en) * | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| JP6348064B2 (ja) * | 2011-11-22 | 2018-06-27 | ザ チルドレンズ ホスピタル オブ フィラデルフィア | 効率の高いトランスジーン送達のためのウイルスベクター |
| US9636370B2 (en) * | 2012-09-28 | 2017-05-02 | The University Of North Carolina At Chapel Hill | AAV vectors targeted to oligodendrocytes |
| WO2015191508A1 (en) * | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2017015102A1 (en) * | 2015-07-17 | 2017-01-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for achieving high levels of transduction in human liver cells |
-
2018
- 2018-02-15 BR BR112019016769-2A patent/BR112019016769A2/pt not_active Application Discontinuation
- 2018-02-15 CN CN202410828011.2A patent/CN118978574A/zh active Pending
- 2018-02-15 MX MX2019009720A patent/MX2019009720A/es unknown
- 2018-02-15 WO PCT/US2018/018381 patent/WO2018152333A1/en not_active Ceased
- 2018-02-15 AU AU2018221738A patent/AU2018221738B2/en not_active Ceased
- 2018-02-15 EA EA201991911A patent/EA038695B1/ru unknown
- 2018-02-15 IL IL312788A patent/IL312788A/en unknown
- 2018-02-15 IL IL268534A patent/IL268534B2/en unknown
- 2018-02-15 JP JP2019542561A patent/JP7291397B2/ja active Active
- 2018-02-15 US US16/485,094 patent/US11905312B2/en active Active
- 2018-02-15 SG SG11201907298WA patent/SG11201907298WA/en unknown
- 2018-02-15 CN CN201880025093.XA patent/CN110520536B/zh not_active Expired - Fee Related
- 2018-02-15 CA CA3052829A patent/CA3052829A1/en active Pending
- 2018-02-15 EP EP18754551.2A patent/EP3583220A4/en not_active Withdrawn
- 2018-02-15 KR KR1020197025393A patent/KR20190117571A/ko active Pending
-
2023
- 2023-01-20 JP JP2023007075A patent/JP7574508B2/ja active Active
-
2024
- 2024-01-10 US US18/409,304 patent/US20240209031A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018152333A9 (en) | 2019-01-24 |
| EP3583220A1 (en) | 2019-12-25 |
| JP2020505936A (ja) | 2020-02-27 |
| IL312788A (en) | 2024-07-01 |
| EA201991911A1 (ru) | 2020-02-20 |
| JP7574508B2 (ja) | 2024-10-29 |
| KR20190117571A (ko) | 2019-10-16 |
| BR112019016769A2 (pt) | 2020-05-26 |
| US11905312B2 (en) | 2024-02-20 |
| IL268534A (en) | 2019-09-26 |
| JP7291397B2 (ja) | 2023-06-15 |
| CA3052829A1 (en) | 2018-08-23 |
| JP2023052541A (ja) | 2023-04-11 |
| EA038695B1 (ru) | 2021-10-06 |
| AU2018221738B2 (en) | 2024-06-27 |
| AU2018221738A1 (en) | 2019-08-22 |
| WO2018152333A1 (en) | 2018-08-23 |
| MX2019009720A (es) | 2019-10-07 |
| CN110520536A (zh) | 2019-11-29 |
| CN118978574A (zh) | 2024-11-19 |
| IL268534B1 (en) | 2024-06-01 |
| US20240209031A1 (en) | 2024-06-27 |
| IL268534B2 (en) | 2024-10-01 |
| US20190367562A1 (en) | 2019-12-05 |
| EP3583220A4 (en) | 2021-07-07 |
| CN110520536B (zh) | 2024-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908280SA (en) | "chimeric molecules and uses thereof" | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201808196UA (en) | Neoantigens and methods of their use | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201805835WA (en) | Modified oncolytic virus | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201808314QA (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy |